Management recommendations for adjuvant systemic breast cancer therapy

Breast Disease

Volumn 21, Issue , 2004, Pages 15-21

  Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adjuvant therapy; Anti estrogens; Breast cancer; Chemotherapy

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ARTICLE; ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; COOPERATION; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LYMPH NODE METASTASIS; MASTECTOMY; MEDICAL DECISION MAKING; MENOPAUSE; META ANALYSIS; OVARIECTOMY; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEPSIS; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 12444261823     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-2004-21103     Document Type: Article

References (31)

1. A. Jemal, T. Murray, A. Samuels, A. Ghafoor, E. Ward and M. Thun, Cancer Statistics, 2003, CA Cancer J Clin 53 (2003), 5-6.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Polychemotherapy for early breast cancer: An overview of the randomized trials, Lancet 352(9132) (1998), 930-942.
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: An overview of the randomized trials, Lancet 351(9114) (1998), 1451-1467.
4. National Institutes of Health Consensus Development. National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000, J Natl Cancer Inst 93 13) (2001), 979-989.
5. A. Goldhirsch, J.H. Glick, R.D. Gelber and H.J. Senn, Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer, J Natl Cancer Inst 90(21) (1998), 1601-1608.
6. W. Jonat, M. Kaufmann, R. Sauerbrei et al., Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy in Premenopausal Patients with Node-Positive Breast Cancer: The Zoladex Early Breast Cancer Research Association Study, J Clin Oncol 20 24) (2002), 4628-4635.
7. R. Jakesz, H. Hausmaninger, E. Kubista et al., Randomized Adjuvant Trial of Tamoxifen and Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the Superiority of Treatment with Endocrine Blockade in Premenopausal Patients with Hormone-Responsive Breast Cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5, J Clin Oncol 20(24) (2002), 4621-4627.
8. B. Fisher, S. Anderson, E. Tan-Chiu, N. Wolmark et al., Tamoxifen and Chemotherapy for Axillary Node-Negative, Estrogen Receptor-Negative Breast Cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-23, J Clin Oncol 19(4) (2001), 931-942.
9. L. Hutchins, S. Green, P. Ravdin et al., CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of Intergroup trial INT 0102, Proc Am Soc Clin Oncol 17 (1998), la.
10. K.I. Pritchard, M.N. Levine, V.H.C. Bramwell et al., A randomized trial comparing CEF to CMF in premenopausal women with node positive breast cancer: Update of NCIC CTG MA.5. SABCS 2002.
11. The ATAC (Arimidex, Tamoxifen Alone or in Combination Trialists Group) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomized trial, Lancet 359 9324) (2002), 2131-2139.
12. The ATAC (Arimidex, Tamoxifen Alone or in Combination Trialists Group) Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: A sub-protocol of the Arimidex and Tamoxifen Alone or in Combination (ATAC) trial, Br J Cancer 85(3) (2001), 317-324.
13. R. Peto, EBCTGG: Updated results from September 2000 worldwide overview, Eur J Cancer 36(Suppl 5) (2000), 847.
14. B.A. Mincey, F.M. Palmieri and E.A. Perez, Adjuvant Therapy for Breast Cancer: Recommendations for Management Based on Consensus Review and Recent Clinical Trials, The Oncologist 7 (2002), 246-250.
15. E.A. Perez, Incorporation of Taxanes in the Adjuvant Management of Patients with Breast Cancer: 2000 NIH Consensus Development Conference, Advances in Breast Cancer 3(2) (2001), 2-5.
16. C.I. Henderson, D.A. Berry, G.D. Demetri et al., Improved Outcomes from Adding Sequential Paclitaxel but not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients with Node-positive Primary Breast Cancer, J Clin Oncol (2003), in press.
17. E.P. Mamounas, J. Bryant, B.C. Lembersky et al., Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. ASCO 2003, abstract #12.
18. J.M. Nabholtz, J. Pienkowski, M. Mackey et al., Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: Interim analysis of the BCIRG001 study, Proc Am Soc Clin Oncol 21(1) (2002), 36a.
19. M.L. Citron, D.A. Berry, C. Cirrincione et al., Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as post-operative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741, J Clin Oncol 21 7) (2003), in press.
20. E.A. Perez, Adjuvant Therapy Approaches to Breast Cancer: Should Taxanes be Incorporated? Curr Oncol Rep 5 (2003), 66-71.
21. E.A. Perez, HER-2 as a Prognostic, Predictive, and Therapeutic Target in Breast Cancer, Cancer Control 6(3) (1999), 233-240.
22. E.A. Perez, Adjuvant anti-HER2 monoclonal antibody therapy-ready for breast cancer? The Breast 10(Suppl 3) (2001), 161-163.
23. E.A. Perez, Phase III trial of doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel with or without trastuzumab as adjuvant treatment for patients with HER2 overexpressing or amplified node positive breast cancer. (N9831) (IRB 1770-1799). www.
24. +) and gene amplification by fluorescence in situ hybridization, Mayo Clin Proc 77 (2002), 148-154.
25. L.F. Hutchins, J.M. Unger, J.J. Crowley, C.A. Coltman and K.S. Albain, Under-representation of patients 65 years or older in cancer-treatment trials, N Engl J Med 341 (1999), 2061-2067. (PMID: 10615079).
26. H.B. Muss, The role of chemotherapy and adjuvant therapy in the management of breast cancer in older women, Cancer 74 (1994), 2165-2171. (PMID: 11773294).
27. H.B. Muss, Chemotherapy of breast cancer in older patients, Semin Oncol 22 (1995), 14-16. (PMID: 7863346).
28. E.A. Perez, C.L. Vogel, D.H. Irwin, J.J. Kirshner and R. Patel, Weekly Paclitaxel in Women Age 65 and above with Metastatic Breast Cancer, Breast Cancer Res and Treat 73(1) (2002), 85-88.
29. +) breast cancer (BC) get similar benefits from adjuvant chemotherapy (Adj) as younger patients (pts): The Cancer and Leukemia Group B (CALBG) experience. ASCO 2003, abstract #11.
30. X.L. Du, C.R. Key, C. Osborne, J.D. Mahken and J.S. Goodwin, Discrepancy between Consensus Recommendations and actual community use of adjuvant chemotherapy in women with breast cancer, Ann Intern Med 138 (2003), 90-97.
31. K.S. Albain, S.J. Green, P.M. Ravdin, C.D. Bobau, E.G. Levine, J.N. Ingle et al., Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent; initial results from Intergroup trial 0100 (SWOG-5814), Proc Am Soc Clin Oncol 21 1) (2002), 37a.